NasdaqHealth CareHealth Care EquipmentS&P SmallCap 600
$303.47
+3.65 (+1.22%)
Close of Nov 06, 2026 · end-of-day data
UFPT 8-K filings in 2025
Every material Form 8-K UFP Technologies filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
UFP Technologies said CEO R. Jeffrey Bailly will retire at the annual stockholders meeting scheduled for June 4, 2026, and that President Mitchell Rock will become CEO and join the Board at that time. Bailly will serve as Executive Chairman for the following year. The filing says his retirement was not due to any disagreement with the company, including on accounting principles and practices, and the change sets a planned succession for shareholders.
Bailly retires as CEO effective at the annual meeting scheduled for June 4, 2026, and will remain on the Board as Executive Chairman.
Mitchell Rock, 58, joined the company in 1991 and has been President since February 2024; his CEO appointment is subject to signing an employment offer letter.
The company's press release says revenue grew about 20-fold and profitability and market capitalization grew more than 150-fold during Bailly's 31 years as CEO.
UFP Technologies reported third-quarter 2025 sales of $154.6 million, up 6.5%, while net income of $16.4 million and diluted EPS of $2.11 were flat with a year earlier. Higher costs, including about $3 million in incremental labor expense at its Illinois AJR facility, pushed gross margin down to 27.7% and operating income down 5.6%. Nine-month sales rose 26.0% to $453.9 million and diluted EPS rose to $6.52 from $5.49, though the filing gives no forward guidance.
Q3 2025 sales were $154.6 million, up 6.5% from $145.2 million; organic sales were essentially flat.
Q3 diluted EPS was $2.11, the same as Q3 2024; adjusted EPS was $2.39 versus $2.49.
Gross margin fell to 27.7% from 28.6%, and about $3 million in incremental labor cost was incurred at the AJR facility.
Nine-month net income was $50.7 million, or $6.52 per diluted share, versus $42.6 million, or $5.49, a year earlier.
UFP Technologies reported second-quarter 2025 net income of $17.2 million, or $2.21 per diluted share, up from $13.6 million, or $1.75, a year earlier. Sales rose 37.2% to $151.2 million, helped by two acquisitions and 4.9% organic growth, while gross margin fell to 28.8% from 30.0%.
Q2 sales increased 37.2% to $151.2 million from $110.2 million; organic sales growth was 4.9%.
Q2 net income was $17.2 million, or $2.21 per diluted share, versus $1.75 a year earlier; adjusted EPS rose 27% to $2.50.
Gross margin fell to 28.8% from 30.0%, including about $1.2 million in incremental labor costs at its AJR facility, which the company expects to be the low point in Q3.
UFP Technologies reported first-quarter 2025 results, with net sales of $148.1 million, up 41.1% from $105.0 million a year earlier, and net income of $17.2 million, or $2.21 per diluted share, versus $1.64 in the first quarter of 2024. Organic sales growth was 2.3%, and gross margin edged down to 28.5% from 28.6%. The press release does not include financial guidance.
Net sales rose 41.1% to $148.1 million for the quarter ended March 31, 2025, from $105.0 million; medical market sales rose 50.4% to $135.4 million.
Net income rose 35.4% to $17.2 million, and diluted EPS was $2.21 versus $1.64 a year earlier.
Organic sales growth was 2.3%, and gross margin was 28.5% versus 28.6% in the first quarter of 2024.
Long-term debt, excluding current installments, was $170.3 million at March 31, 2025, down from $176.9 million at December 31, 2024.
On March 31 and March 26, 2025, subsidiary AJR Enterprises signed two supply agreements with Sage Products, LLC (Stryker), the company's second-largest customer. Stryker agreed to buy 100% of its requirements for certain products from AJR on an exclusive basis, and the company agreed to buy the equipment needed to make them and to move that manufacturing to the Dominican Republic over two years. The filing does not disclose revenue or dollar amounts for the agreements.
March 31, 2025 agreement: exclusive purchase commitment for a 42-month period starting January 1, 2026.
March 26, 2025 amended agreement: exclusive purchase commitment for about 63 months, effective April 24, 2024.
Company will move manufacturing to the Dominican Republic over the next two years; Stryker is eligible for price reductions as products transfer.
Stryker's purchase requirement ends if certain events occur, such as the company failing to meet regulatory or quality requirements.
UFP Technologies disclosed that Steve Cardin, its Vice President and Chief Operating Officer of the MedTech business, resigned on March 15, 2025. His last day with the company will be March 28, 2025. The filing does not name a successor or describe the reasons for the departure.
Steve Cardin, Vice President and Chief Operating Officer of the MedTech business, tendered his resignation on March 15, 2025
Last day with the company will be March 28, 2025
The filing does not name a replacement or give a reason for the departure
UFP Technologies reported fourth-quarter and full-year 2024 results on February 25, 2025. Full-year net sales rose 26.1% to $504.4 million and GAAP diluted EPS was $7.58, compared with $5.83 in 2023, while fourth-quarter sales grew 41.9% to $144.1 million. Long-term debt, less current portion, was $176.9 million at December 31, 2024, up from $28.0 million a year earlier.
Full-year 2024 net income was $59.0 million, up 31.3% from $44.9 million; GAAP diluted EPS was $7.58 versus $5.83.
Fourth-quarter 2024 net sales were $144.1 million, up 41.9%; GAAP diluted EPS was $2.10 versus $1.51.
Full-year MedTech sales rose 30.2% to $450.8 million; gross margin was 29.1% versus 28.1%.
Long-term debt, less current portion, was $176.9 million at December 31, 2024, versus $28.0 million at December 31, 2023.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every UFP Technologies filing is on SEC EDGAR ↗. 8-K briefs of other companies →